Presynaptic Imaging in Major Depressive Episodes After COVID-19
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID-DNP). COVID-DNP encompasses major depressive episodes (MDE) with or without additional neuropsychiatric symptoms.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: t
View:
• New onset MDE within 3 months after mild or moderate COVID-19, with MDE verified by the research version SCID for DSM 5. See Positive COVID-19 diagnosis listed after inclusion/exclusion criteria for a description of how this is determined.
• Age 18 to 75.
• Good general physical health with no active medical conditions based on self-report (except migraine or PASC).
Locations
Other Locations
Canada
Centre for Addiction and Mental Health
RECRUITING
Toronto
Contact Information
Primary
Karida Liu
liuyuhan0830@gmail.com
416-535-8501
Backup
Jeffrey Meyer
jeffrey.meyer@utoronto.ca
416-535-8501
Time Frame
Start Date: 2023-08-22
Estimated Completion Date: 2025-09-10
Participants
Target number of participants: 90
Treatments
COVID-DNP
Participants that have recovered from mild or moderate COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).
Healthy Control
Participants in good physical health, age- and sex-matched to Group 1 and 2 participants.
Related Therapeutic Areas
Sponsors
Leads: Centre for Addiction and Mental Health